Allogene Therapeutics, Inc. (ALLO) Stock Grade

About Allogene Therapeutics, Inc.'s fundamentals

Allogene Therapeutics is a biotechnology company with a market capitalization of $302.3 million that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of 0.0%. The company experienced a significant operational change, with revenue declining 100% year-over-year, indicating it is no longer generating product revenue. The company does not pay a dividend and traditional valuation metrics like P/E ratio and return on equity are not applicable given its loss-making status. As an early-stage or restructuring biotech firm, investors should note that profitability and positive cash flow remain absent from current financials.